Cognitive decline is believed to be associated with neurodegenerative processes involving
excitotoxicity, oxidative damage, inflammation, and microvascular and blood-brain barrier …

Introduction The endocannabinoid (eCB) system disruption has been suggested to underpin
the development of psychosis, fueling the search for novel, better-tolerated antipsychotic …

Objectives Studies have suggested that fingolimod, a sphingosine-1-phosphate receptor
modulator, exerts neuroprotective and anti-inflammatory effects. Although fingolimod is …

Background Clinical trials of anti-inflammatories in schizophrenia do not show clear and
replicable benefits, possibly because patients were not recruited based on elevated …

Schizophrenia (SCZ) imposes a significant burden on patients and their families because of
its high prevalence rate and disabling nature. Given the lack of definitive conclusions …

Introduction The severity of positive symptoms in schizophrenia is associated with poor
prognosis. About one-third of schizophrenia patients partially respond to treatment with …

Schizophrenia is a chronic and progressive disorder characterized by cognitive, emotional,
and behavioral abnormalities associated with neuronal development and synaptic plasticity …

Background Antipsychotics are the gold standard treatment for schizophrenia, but many
patients who receive treatment experience persistent symptoms. The aim of this network …

Interest in preventative dietary interventions for human health has increasingly focused on
the endocannabinoid (eCB)-like compound palmitoylethanolamide (PEA), a bioactive lipid …

The present studies were undertaken to understand the effects of the commonly used
nutraceutical PEA on brain function and lipid chemistry. These studies using MRI and broad …